See how Luneri turns one flagged biomarker into a clearer next step.
A focused demo case built from the real Analyze interpretation layer. LDL-C is the main out-of-range signal, with companion markers included for context.
Simulated sample data for educational preview only. This is not a diagnosis, treatment plan, or replacement for clinical review.
This sample uses a fixed example panel while the interpretation layer still runs through the real analysis engine.
The demo case uses fixed biomarker inputs, but the interpretation layer uses the same deterministic analysis engine and dossier-linked mapping as the main product.
Sample panel
Sample cardiometabolic review
LDL Cholesterol
LDL
170
mg/dL
Above the current reference window.
Reference < 100
170 mg/dL
HDL Cholesterol
HDL
52
mg/dL
Inside the current reference window.
Reference > 40
52 mg/dL
Triglycerides
TG
118
mg/dL
Inside the current reference window.
Reference < 150
118 mg/dL
Fasting Glucose
Glucose
92
mg/dL
Inside the current reference window.
Reference < 100
92 mg/dL
High-Sensitivity CRP
hs-CRP
1.4
mg/L
Above the current reference window.
Reference < 1
1.4 mg/L
Flagged biomarker
LDL needs intervention
LDL is 70% above 100 mg/dL at 170 mg/dL.
Top surfaced direction
Magnesium
LDL-C: small effect signal; meta-analysis or randomized trial evidence; dyslipidemia and cardiometabolic risk.
Why this surfaced
Chosen because indexed human evidence maps it to lowering LDL, and LDL-C: small effect signal; meta-analysis or randomized trial evidence; dyslipidemia and cardiometabolic risk.
Safety watch-out
LDL-C: small effect signal; adult dyslipidemia and hypertriglyceridemia contexts.
Report workflow preview
The report engine turns the same sample markers into ranked options, protocol hints, and caveats.
This preview is deterministic and evidence-linked. It is not a diagnosis, treatment plan, or replacement for clinical review.
Report structure is real; the biomarker values on this page are demo data for workflow preview only.
Biomarker priorities
3 surfacedLDL
LDL is high and is a primary Cardiometabolic marker.
hs-CRP
hs-CRP is high and is a primary Cardiometabolic marker.
HDL
HDL is normal and is a primary Cardiometabolic marker.
Evidence-ranked options
3 candidatesBerberine
Berberine matches hs-CRP with a A-grade decrease signal.
L Carnitine
L Carnitine matches hs-CRP with a A-grade decrease signal.
Taurine
Taurine matches hs-CRP with a A-grade decrease signal.
Protocol seed hints
glycemic control
500 mg berberine HCl
General health supplementation — lipid optimization, anti-inflammatory support, metabolic health
1000–2000 mg/day
Safety and uncertainty
pgx-review
Unmapped biomarker signal: 8-ohdg
Unmapped biomarker signal: abeta-burden
7 ranked interventions used registry fallback provenance.
Unmapped biomarker signal: 8-ohdg
Full report sections
Clinical triage
1 marker needs attention now, with 1 additional marker worth addressing.
This analysis is generated by deterministic biomarker logic using dossier-linked intervention mapping.
Next steps
Clinical handoffs
Move from interpretation into research review, protocol construction, or follow-through.
Build seeded protocol
Seed the protocol builder with the strongest overlap and priority compounds.
Recheck in 8-12 weeks
Follow through with ApoB, TG for a cleaner read on improvement.
Add more markers
Return to intake without clearing the current manual set and widen prioritization.
LDL
LDL Cholesterol
LDL is 70% above 100 mg/dL at 170 mg/dL.
Low-density lipoprotein cholesterol; primary atherogenic particle
Current value
170
mg/dL
70% above boundary
Reference < 100
170 mg/dL
Clinical meaning
Use Magnesium and Zinc as the first research-backed directions to lower LDL.
Reference < 100 mg/dL | Optimal < 70 mg/dL
Reference context
Reference < 100 mg/dL | Optimal < 70 mg/dL
Use Magnesium and Zinc as the first research-backed directions to lower LDL.
Recommended direction
Decision-oriented interventions prioritized by evidence strength, role, and current marker fit.
Magnesium
MetabolicPrimaryDerivedGlycinate and L-Threonate
Targets
LDLChosen because indexed human evidence maps it to lowering LDL, and LDL-C: small effect signal; meta-analysis or randomized trial evidence; dyslipidemia and cardiometabolic risk.
LDL-C: small effect signal; meta-analysis or randomized trial evidence; dyslipidemia and cardiometabolic risk.
Some supporting biomarker mappings still fall back to the registry while dossier normalization is incomplete (65 unmapped signals).
Zinc
NutraceuticalAdjunctDerivedStructured dossier entry
Targets
LDLChosen because indexed human evidence maps it to lowering LDL, and LDL-C: Pooled WMD −0.20 to −0.38 mmol/L in T2D; inconsistent in non-diabetic populations; dose-response suggests stronger effect at higher doses; meta-analysis; T2D, dyslipidemia, adults.
LDL-C: Pooled WMD −0.20 to −0.38 mmol/L in T2D; inconsistent in non-diabetic populations; dose-response suggests stronger effect at higher doses; meta-analysis; T2D, dyslipidemia, adults.
Dossier biomarker normalization still has 14 unmapped signals under review.
Zone 2 Cardio
ExerciseOptionalDerivedbehavioral intervention
Targets
LDLChosen because indexed human evidence maps it to lowering LDL, and LDL-C: MD −0.1 to −0.3 mmol/L in overweight/obese; HIIT may produce larger LDL-C reductions than energy-matched MICT (Vella 2017: HIIT −0.66 vs MICT −0.03 mmol/L, p<0.05 in n=17); inconsistent with Wood 2019 MA showing no HIIT superiority for lipids — small sample signal only; meta-analysis; adults overweight obese, adults dyslipidemia.
LDL-C: MD −0.1 to −0.3 mmol/L in overweight/obese; HIIT may produce larger LDL-C reductions than energy-matched MICT (Vella 2017: HIIT −0.66 vs MICT −0.03 mmol/L, p<0.05 in n=17); inconsistent with Wood 2019 MA showing no HIIT superiority for lipids — small sample signal only; meta-analysis; adults overweight obese, adults dyslipidemia.
Safety watch-out
Omega 3 may push this marker in the wrong direction.
LDL-C: small effect signal; adult dyslipidemia and hypertriglyceridemia contexts.
Dossier biomarker normalization still has 58 unmapped signals under review.
Clinical follow-through
Recheck in 8-12 weeks
Improvement looks like LDL-C moving back toward range while ApoB and triglycerides trend in the same direction.
hs-CRP
High-Sensitivity CRP
hs-CRP is 40% above 1 mg/L at 1.4 mg/L.
Sensitive systemic inflammation marker; CVD risk predictor
Current value
1.4
mg/L
40% above boundary
Reference < 1
1.4 mg/L
Clinical meaning
Use Creatine and NAC as the first research-backed directions to lower hs-CRP.
Reference < 1 mg/L | Optimal < 0.5 mg/L
Reference context
Reference < 1 mg/L | Optimal < 0.5 mg/L
Use Creatine and NAC as the first research-backed directions to lower hs-CRP.
Recommended direction
Decision-oriented interventions prioritized by evidence strength, role, and current marker fit.
Creatine
RecoveryPrimaryDerivedMonohydrate
Targets
hs-CRPChosen because indexed human evidence maps it to lowering hs-CRP, and hs-CRP: small effect signal; meta analysis; healthy adults, athletes, older adults.
hs-CRP: small effect signal; meta analysis; healthy adults, athletes, older adults.
Some supporting biomarker mappings still fall back to the registry while dossier normalization is incomplete (36 unmapped signals).
NAC
HepaticAdjunctDerivedN-Acetyl Cysteine
Targets
hs-CRPChosen because indexed human evidence maps it to lowering hs-CRP, and hs-CRP: moderate; randomized trial pooled; adult, renal failure, pcos.
hs-CRP: moderate; randomized trial pooled; adult, renal failure, pcos.
Dossier biomarker normalization still has 68 unmapped signals under review.
HIIT Training
ExerciseOptionalDerivedbehavioral intervention
Targets
hs-CRPChosen because indexed human evidence maps it to lowering hs-CRP, and hs-CRP: Pooled MD ~-0.5 to -1.5 mg/L in overweight/obese and metabolic disease; SMD ~-0.5; HIIT comparable to or modestly superior to MICT; obese children: MD ~-0.4 mg/L; multiple meta analyses; overweight obese, t2dm, metabolic syndrome.
hs-CRP: Pooled MD ~-0.5 to -1.5 mg/L in overweight/obese and metabolic disease; SMD ~-0.5; HIIT comparable to or modestly superior to MICT; obese children: MD ~-0.4 mg/L; multiple meta analyses; overweight obese, t2dm, metabolic syndrome.
Next step
Create a free account to move from a sample case into your own research workflow.
Start free, keep browsing dossiers, and unlock deeper analysis or protocol workflows when you are ready.
The preview above uses demo values; your Analyze workspace starts with your own entered labs.